ABG Innovation Capital Partners III GP Ltd Long-Term Concentrated

CIK: 0001845297 · Show all filings

Period: Q3 2021 (← Previous) (Next →)

Filing Date: Nov 15, 2021

Total Value ($000): $2,407 (100.0% shares, 0.0% debt)

Holdings (6)

WHWK AADI BIOSCIENCES INC 32.5%

Value ($000) $783 Shares 26,666 Est. Cost $30.48 Unrealized 0.0%

GNCAQ GENOCEA BIOSCIENCES INC 29.9%

Value ($000) $720 Shares 375,000 Est. Cost $2.28 Unrealized -13.7%

— SYNLOGIC INC 26.1%

Value ($000) $628 Shares 205,906 Est. Cost $2.16 Unrealized —

LUNG PULMONX CORP 6.8%

Value ($000) $163 Shares 4,521 Est. Cost $48.97 Unrealized -19.7%

— IDERA PHARMACEUTICALS INC 2.4%

Value ($000) $58 Shares 56,250 Est. Cost $3.66 Unrealized —

— NABRIVA THERAPEUTICS PLC 2.3%

Value ($000) $55 Shares 45,849 Est. Cost $2.42 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
WHWK	AADI BIOSCIENCES INC	26,666	$783	32.5%	$30.48	0.0%	COM	00032Q104
GNCAQ	GENOCEA BIOSCIENCES INC	375,000	$720	29.9%	$2.28	-13.7%	COM NEW	372427401
—	SYNLOGIC INC	205,906	$628	26.1%	$2.16	—	COM	87166L100
LUNG	PULMONX CORP	4,521	$163	6.8%	$48.97	-19.7%	COM	745848101
—	IDERA PHARMACEUTICALS INC	56,250	$58	2.4%	$3.66	—	COM PAR	45168K405
—	NABRIVA THERAPEUTICS PLC	45,849	$55	2.3%	$2.42	—	SHS	G63637113